<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00257309</url>
  </required_header>
  <id_info>
    <org_study_id>EUDRACT 2004-001943-31</org_study_id>
    <secondary_id>FIS PI042122</secondary_id>
    <nct_id>NCT00257309</nct_id>
  </id_info>
  <brief_title>Thrombolysis Versus Primary Angioplasty for AMI in Elderly Patients</brief_title>
  <acronym>TRIANA</acronym>
  <official_title>TRIANA: A Randomized Trial to Compare the Efficay and Safety of Thrombolysis With Primary Angioplasty as Initial Reperfusion Therapy in Older Patients (&gt;= 75 Years Old) With Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Society of Cardiology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondo de Investigacion Sanitaria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cordis Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guidant Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Society of Cardiology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      General objective: To compare the efficacy and safety of primary angioplasty(PA) with that of
      thrombolytic therapy (TT) for the treatment of AMI in patients &gt;=75 years old with ST-segment
      elevation or LBBB AMI &lt;6 hours of evolution without contraindications for TT.

      Hypothesis: The therapeutical strategy based on PA is superior to that based initially on TT
      in patients &gt;=75 years old with AMI.

      Participating Centers: 27 Spanish hospitals performing &gt;50 PA/year. Primary Endpoint (PE):
      Incidence of the aggregate of death of any cause, reinfarction or disabling stroke at 30
      days. There are also 7 secondary endpoints (SE).

      Procedure: Diagnosis of inclusion/exclusion criteria --&gt; Centralized randomization --&gt;
      Treatment allocation to 1) TT with weight adjusted TNK + unfractionated heparin or 2) PA
      within 120 minutes. Estimated Sample size and recruitment time: 570 patients in 19 months.
      Follow-up: Blinded evaluation of events (PROBE regulations) specified in PE and SE at 30 days
      and 12 months. Quality control: 100% variable and follow-up review by external CRO. Safety
      Committee and Event Adjudication Committee formed by experts not participating in the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis of the study. In patients of 75 or more years of age with AMI and ST-elevation or
      LBBB, the treatment strategy based on primary angioplasty is superior to the treatment
      strategy based on initial fibrinolytic therapy for reducing the incidence of death,
      re-infarction and disabling CVA at 30 days. This benefit is maintained at 12 months.

      Objectives General objective of the study. To compare the efficacy and safety of primary
      angioplasty and fibrinolytic treatment in &gt;=75 year-old patients with AMI eligible for
      fibrinolytic therapy in Spanish medical centers with an active program of primary
      angioplasty.

      Primary end point: Incidence of the combined end point of all-cause death, re-infartion or
      disabling stroke at 30 days

      Secondary end points:

        -  All-cause death at 30 days

        -  Incidence of the combined end point of all-cause death, disabling CVA or de novo heart
           failure at 30 days

        -  Incidence of recurrent ischemia requiring emergency catheterization in the first 30 days

        -  Cause of death at 30 days classified in three groups:

             1. Shock or heart (pump) failure

             2. Mechanical complications (ruptures) or electromechanical dissociation

             3. Other causes (including bleeding)

        -  Incidence of major bleeding during hospital admission

        -  All-cause mortality at 12 months

        -  Period of time elapsed until presentation of any of the composite of all-cause death,
           reinfarction or disabling CVA at 12 months

        -  Period of time elapsed until the presentation of any composite of all-cause death,
           reinfarction, disabling CVA or non-elective hospital readmission for cardiac causes
           (unstable angina, heart failure, non-elective coronary revascularization at 12 months.

      TYPE AND DESIGN OF THE CLINICAL TRIAL Clinical trial status Phase IV trial Description of
      randomization process The treatment strategy will be determined by a centralized
      randomization process, using a telephone system. Eligible patients will be randomized to one
      of two (2) treatment arms: fibrinolytic treatment or primary angioplasty.

      Control and design This is a randomized multicenter, open blind clinical trial designed to
      compare the efficacy and safety of primary angioplasty vs. thrombolytic treatment in &gt;=75
      year-old patients with AMI and ST-elevation or de novo LBBB, eligible for thrombolysis,
      admitted at Spanish medical centers that have an active primary angioplasty program, within
      the first 6 hours after symptom onset.

      Masking techniques Being an open trial there are not masking techniques, nor will there be an
      emergency opening procedure of emergency codes.

      Pre-inclusion / clearance period Not applicable

      SUBJECT SELECTION Inclusion / exclusion criteria Subjects must be &gt;=75 years of age with AMI
      and ST-elevation or de novo LBBB, eligible for thrombolytic therapy, admitted in any Spanish
      medical center in which there is an active primary angioplasty program within the first 6
      hours after symptom onset.

      Each patient must fulfill all inclusion criteria and none of the exclusion criteria.

      Inclusion criteria:

        1. Subjects of 75 or more years of age

        2. Diagnosis of AMI: chest pain or any symptom of myocardial ischemia of, at least, 20
           minutes of duration, not responding to nitrate therapy, an evolution period of less than
           6 hours after symptom onset until randomization process, and, at least, one of the
           following alterations:

             1. ST-elevation &gt;=2 mm in 2 or more precordial leads

             2. ST-elevation &gt;=1 mm in 2 or more anterior leads

             3. Complete de novo (or probably de novo) left bundle branch block (LBBB)

        3. Subject should be able to give informed consent prior to randomization process and
           should agree to fulfill all procedures described in the protocol, including follow-up
           after hospital discharge. A written consent signed by a close relative with witness is
           also acceptable.

      Exclusion criteria:

        1. Documented contraindication to the use of fibrinolytics. 1.1. Internal active bleeding
           or known history of hemorrhagic diathesis 1.2. History of previous CVA of any kind or at
           any time 1.3. Intracranial tumor, arteriovenous malformation, aneurysm or cerebral
           aneurysm repair 1.4. Major surgery, parenchymal biopsy, ocular surgery or severe
           traumatism in the 6 weeks prior to randomization 1.5. Unexplained puncture in a
           non-compressible vascular location in the last 24 hours prior to randomization 1.6.
           Confirmed arterial hypertension with a reliable measurement of systolic AP &gt;180 mmHg or
           diastolic AP &gt;110 mmHg 1.7. Known thrombocytopenia &lt; 100.000 platelets/mL 1.8. Prolonged
           (&gt;20 minutes) or traumatic cardiopulmonar resuscitation (CPR) in the 2 weeks prior to
           randomization 1.9. History or signs suggesting aortic dissection

        2. Cardiogenic shock

        3. Estimated door-to-needle time &gt;120 minutes

        4. Administration of fibrinolysis in the 14 days prior to randomization

        5. Administration of any glycoprotein IIa/IIIb inhibitor in the 24 hours prior to
           randomization

        6. Administration of any Low Molecular Weight Heparin (LMWH) in the 8 hours prior to
           randomization

        7. Actual oral anticoagulant treatment

        8. Suspected AMI secondary to occlusion of one lesion treated previously with a
           percutaneous coronary intervention (within the previous 30 days for angioplasty or
           conventional stent and within the previous 12 months for coated stents)

        9. Dementia or acute confusional state at the time of randomization

       10. Subject incapacity or unwillingness to give informed consent -at least, verbally

       11. Known renal failure (basal creatinine&gt; 2,5 mg/dl)

       12. Reduced life expectancy (&lt;12 months) due to advanced or terminal concomitant condition

       13. Subject participation in another clinical trial (assessing a drug or a device) in the 30
           days prior to randomization

      Diagnostic criteria for the pathologies of the study

      Patients with a diagnosis of AMI presenting with:

        -  Chest pain or any symptom of myocardial ischemia of, at least, 20 minutes of duration,
           not responding to nitrate therapy and an evolution period of less than 6 hours after
           symptom onset until randomization process, with, at least, one of the following
           alterations:

        -  ST-elevation &gt;=2 mm in 2 or more precordial leads

        -  ST-elevation &gt;=1 mm in 2 or more anterior leads

        -  Complete de novo (or probably de novo) left bundle branch block (LBBB)

      Estimate of sample size For the following conditions: α = 0.05 (2 tailed), power: 80% (β =
      0.20) and assuming a composite event incidence rate (death, reinfarction and disabling CVA)
      based on previous registries (21.7% in the fibrinolysis group and 12.8% in the PA group), a
      sample size of 282 patients per group is needed to demonstrate that difference (8.9% in
      absolute terms and 40% in relative terms). Assuming a loss to follow-up rate of 1%, the total
      number is 570 patients

      Estimated loss of patients prior to randomization During a period of 3 months all patients
      meeting inclusion criteria who, for any reason, are not enrolled in the study will be
      included in a registry with an abbreviated CRF recording inclusion/exclusion criteria, the
      reason for non-enrollment and follow-up at 30 days and 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow recruitment
  </why_stopped>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Death or Reinfarction or Disabling Stroke</measure>
    <time_frame>30 days</time_frame>
    <description>Incidence of all-cause death or myocardial reinfarction or disabling stroke</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death/Reinfarction/Disabling Stroke at 30 Days</measure>
    <time_frame>30 days</time_frame>
    <description>Incidence of Death or Reinfarction or Disabling Stroke at 30 days</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">266</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Thrombolysis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Weight adjusted tenecteplase bolus + Unfrationated heparin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primary angioplasty</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Primary angioplasty</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenecteplase + UFH (+ clopidogrel, since 01/97)</intervention_name>
    <arm_group_label>Thrombolysis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Primary angioplasty</intervention_name>
    <arm_group_label>Primary angioplasty</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          1. Subjects of 75 or more years of age

          2. Diagnosis of AMI: chest pain or any symptom of myocardial ischemia of, at least, 20
             minutes of duration, not responding to nitrate therapy, an evolution period of less
             than 6 hours after symptom onset until randomization process, and, at least, one of
             the following alterations:

               1. ST-elevation &gt;=2 mm in 2 or more precordial leads

               2. ST-elevation &gt;=1 mm in 2 or more anterior leads

               3. Complete de novo (or probably de novo) left bundle branch block (LBBB)

          3. Subject should be able to give informed consent prior to randomization process and
             should agree to fulfill all procedures described in the protocol, including follow-up
             after hospital discharge. A written consent signed by a close relative with witness is
             also acceptable.

        EXCLUSION CRITERIA:

          1. Documented contraindication to the use of fibrinolytics. 1.1. Internal active bleeding
             or known history of hemorrhagic diathesis 1.2. History of previous CVA of any kind or
             at any time 1.3. Intracranial tumor, arteriovenous malformation, aneurysm or cerebral
             aneurysm repair 1.4. Major surgery, parenchymal biopsy, ocular surgery or severe
             traumatism in the 6 weeks prior to randomization 1.5. Unexplained puncture in a
             non-compressible vascular location in the last 24 hours prior to randomization 1.6.
             Confirmed arterial hypertension with a reliable measurement of systolic AP &gt;180 mmHg
             or diastolic AP &gt;110 mmHg 1.7. Known thrombocytopenia &lt; 100.000 platelets/mL 1.8.
             Prolonged (&gt;20 minutes) or traumatic cardiopulmonar resuscitation (CPR) in the 2 weeks
             prior to randomization 1.9. History or signs suggesting aortic dissection

          2. Cardiogenic shock

          3. Estimated door-to-needle time &gt;120 minutes

          4. Administration of fibrinolysis in the 14 days prior to randomization

          5. Administration of any glycoprotein IIa/IIIb inhibitor in the 24 hours prior to
             randomization

          6. Administration of any Low Molecular Weight Heparin (LMWH) in the 8 hours prior to
             randomization

          7. Actual oral anticoagulant treatment

          8. Suspected AMI secondary to occlusion of one lesion treated previously with a
             percutaneous coronary intervention (within the previous 30 days for angioplasty or
             conventional stent and within the previous 12 months for coated stents)

          9. Dementia or acute confusional state at the time of randomization

         10. Subject incapacity or unwillingness to give informed consent -at least, verbally

         11. Known renal failure (basal creatinine&gt; 2,5 mg/dl)

         12. Reduced life expectancy (&lt;12 months) due to advanced or terminal concomitant condition

         13. Subject participation in another clinical trial (assessing a drug or a device) in the
             30 days prior to randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hector Bueno, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spanish Society of Cardiology (WG on Ischemic Heart Disease and CCUs)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rosa Ana Hernández-Antolín, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spanish Society of Cardiology (WG on Interventional Cardiology)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Dureta</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Baleares</state>
        <zip>07003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>La Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de León</name>
      <address>
        <city>Leon</city>
        <state>León</state>
        <zip>24010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario &quot;Virgen de la Victoria&quot;</name>
      <address>
        <city>Malaga</city>
        <state>Málaga</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <state>Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Cruces</name>
      <address>
        <city>Barakaldo</city>
        <state>Vizcaya</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Juan Ramón Jiménez</name>
      <address>
        <city>Huelva</city>
        <zip>21005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario &quot;Juan Canalejo&quot;</name>
      <address>
        <city>La Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario &quot;Gregorio Maranon&quot;</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico &quot;San Carlos&quot;</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Toledo Hospital Virgen de la Salud</name>
      <address>
        <city>Toledo</city>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorcio Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Bardají A, Bueno H, Fernández-Ortiz A, Cequier A, Augé JM, Heras M. [Type of treatment and short-term outcome in elderly patients with acute myocardial infarction admitted to hospitals with a primary coronary angioplasty facility. The TRIANA (TRatamiento del Infarto Agudo de miocardio eN Ancianos) Registry]. Rev Esp Cardiol. 2005 Apr;58(4):351-8. Spanish.</citation>
    <PMID>15847731</PMID>
  </reference>
  <reference>
    <citation>Cequier A, Bueno H, Augé JM, Bardají A, Fernández-Ortiz A, Heras M. [Characteristics and mortality following primary percutaneous coronary intervention for acute myocardial infarction in Spain. Results from the TRIANA 1 (TRatamiento del Infarto Agudo de miocardio eN Ancianos) Registry]. Rev Esp Cardiol. 2005 Apr;58(4):341-50. Spanish.</citation>
    <PMID>15847730</PMID>
  </reference>
  <results_reference>
    <citation>Bueno H, Betriu A, Heras M, Alonso JJ, Cequier A, García EJ, López-Sendón JL, Macaya C, Hernández-Antolín R; TRIANA Investigators. Primary angioplasty vs. fibrinolysis in very old patients with acute myocardial infarction: TRIANA (TRatamiento del Infarto Agudo de miocardio eN Ancianos) randomized trial and pooled analysis with previous studies. Eur Heart J. 2011 Jan;32(1):51-60. doi: 10.1093/eurheartj/ehq375. Epub 2010 Oct 22.</citation>
    <PMID>20971744</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2005</study_first_submitted>
  <study_first_submitted_qc>November 18, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2005</study_first_posted>
  <results_first_submitted>October 2, 2016</results_first_submitted>
  <results_first_submitted_qc>November 22, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 19, 2017</results_first_posted>
  <last_update_submitted>November 22, 2016</last_update_submitted>
  <last_update_submitted_qc>November 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Spanish Society of Cardiology</investigator_affiliation>
    <investigator_full_name>Héctor Bueno</investigator_full_name>
    <investigator_title>(Past) President. WG on IHD</investigator_title>
  </responsible_party>
  <keyword>Acute myocardial infarction</keyword>
  <keyword>Elderly</keyword>
  <keyword>Thrombolysis</keyword>
  <keyword>Primary angioplasty</keyword>
  <keyword>Randomized trial</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Tenecteplase</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Thrombolysis</title>
          <description>Weight adjusted tenecteplase bolus + Unfrationated heparin
Tenecteplase + UFH (+ clopidogrel, since 01/97)</description>
        </group>
        <group group_id="P2">
          <title>Primary Angioplasty</title>
          <description>Primary angioplasty
Primary angioplasty</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="134"/>
                <participants group_id="P2" count="132"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="132"/>
                <participants group_id="P2" count="130"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Thrombolysis</title>
          <description>Weight adjusted tenecteplase bolus + Unfrationated heparin
Tenecteplase + UFH (+ clopidogrel, since 01/97)</description>
        </group>
        <group group_id="B2">
          <title>Primary Angioplasty</title>
          <description>Primary angioplasty
Primary angioplasty</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="134"/>
            <count group_id="B2" value="132"/>
            <count group_id="B3" value="266"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>years of age at randomization</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81.0" spread="4.3"/>
                    <measurement group_id="B2" value="81.2" spread="4.6"/>
                    <measurement group_id="B3" value="81.1" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="150"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Death or Reinfarction or Disabling Stroke</title>
        <description>Incidence of all-cause death or myocardial reinfarction or disabling stroke</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thrombolysis</title>
            <description>Weight adjusted tenecteplase bolus + Unfrationated heparin
Tenecteplase + UFH (+ clopidogrel, since 01/97)</description>
          </group>
          <group group_id="O2">
            <title>Primary Angioplasty</title>
            <description>Primary angioplasty
Primary angioplasty</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Death or Reinfarction or Disabling Stroke</title>
          <description>Incidence of all-cause death or myocardial reinfarction or disabling stroke</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Death/Reinfarction/Disabling Stroke at 30 Days</title>
        <description>Incidence of Death or Reinfarction or Disabling Stroke at 30 days</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thrombolysis</title>
            <description>Weight adjusted tenecteplase bolus + Unfrationated heparin
Tenecteplase + UFH (+ clopidogrel, since 01/97)</description>
          </group>
          <group group_id="O2">
            <title>Primary Angioplasty</title>
            <description>Primary angioplasty
Primary angioplasty</description>
          </group>
        </group_list>
        <measure>
          <title>Death/Reinfarction/Disabling Stroke at 30 Days</title>
          <description>Incidence of Death or Reinfarction or Disabling Stroke at 30 days</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.21</p_value>
            <p_value_desc>Unadjusted analysis</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Thrombolysis</title>
          <description>Weight adjusted tenecteplase bolus + Unfrationated heparin
Tenecteplase + UFH (+ clopidogrel, since 01/97)</description>
        </group>
        <group group_id="E2">
          <title>Primary Angioplasty</title>
          <description>Primary angioplasty
Primary angioplasty</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Major bleeding</sub_title>
                <description>Major haemorrhage</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="134"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Red blood transfusion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="134"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Major hemorrhage or transfusion</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="134"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Mechanical complications</sub_title>
                <description>Cardiac rupture (free wall rupture, interventiruclar septal rupture, papillary muscle rupture)</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="134"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute renal failure</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="134"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Héctor Bueno</name_or_title>
      <organization>Centro Nacional de Investigaciones Cardiovasculares</organization>
      <phone>(+34) 914 531 200 ext 4110</phone>
      <email>hbueno@cnic.es</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

